Understanding how S100A7 affects aggressive breast cancer in African American women
Official title: Unravel the novel role of S100A7 and its functional partners in Metastatic Triple Negative Breast Cancer Racial Disparity
Funded at Ohio State University · NIH-10946343 · Data updated 2026-11-12
This study is looking at a protein called S100A7 and how it affects triple-negative breast cancer, especially in African American women who are more likely to face serious challenges from this disease, with the hope of finding new ways to improve treatment for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $469,544 |
| NIH project number | 1R01CA292020-01 |
| Project ID | NIH-10946343 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American women diagnosed with triple-negative breast cancer.
✕Less likely to help
Patients with non-triple-negative breast cancer or those outside the African American demographic may not benefit from this research.
What this research studies
This research investigates the role of S100A7 in triple-negative breast cancer (TNBC), particularly focusing on its impact on African American women who experience higher mortality rates from this disease. The study explores how S100A7 interacts with immune signaling pathways to create a tumor microenvironment that promotes cancer progression and metastasis. By analyzing patient samples and using pre-clinical models, the researchers aim to uncover mechanisms that contribute to the aggressive nature of TNBC in this population. The ultimate goal is to identify potential therapeutic targets that could improve treatment outcomes for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving aggressive TNBC in African American women.
How similar studies have gone: Previous research has shown promising results in targeting immune pathways in breast cancer, suggesting that this approach may yield significant insights and advancements.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Ganju, Ramesh K. — Ohio State University
- Study coordinator: Ganju, Ramesh K.
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.